In June 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Cabometyx (cabozantinib) for the treatment of adult patients with unresectable or metastatic neuroendocrine tumors. (ema.europa.eu) This development may influence treatment protocols and market dynamics for sorafenib.
In September 2019, the EMA's Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on the orphan designation application for a combination of melatonin and sorafenib for the treatment of hepatocellular carcinoma, citing insufficient evidence of potential efficacy. (ema.europa.eu)
In November 2022, the EMA granted marketing authorization for Sorafenib Accord, a generic version of sorafenib, expanding the availability of this medication within the European Union. (ema.europa.eu)
In May 2019, the FDA approved Cyramza (ramucirumab) for the treatment of patients with hepatocellular carcinoma who have an alpha-fetoprotein of ≥400 ng/mL and have been treated with sorafenib, providing an additional therapeutic option for this patient population.
In January 2019, the FDA approved Cabometyx (cabozantinib) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, further expanding treatment options in this area.
These developments reflect the evolving regulatory and therapeutic landscape surrounding sorafenib, with implications for market access, competition, and treatment strategies globally.
